gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · STIMHealthcareSurgical Instruments

Neuronetics, Inc. Common Stock (STIM)

$2.71+19.69%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$2.71▼ 5.75% in range
Nov 4, 2025Low $1.18 · High $3.30Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Neuronetics closed at $2.71 on Nov 4, up 19.69%, 18.0% below its 52-week closing high. Volume of 5.5M shares was 7.48× its 20-day average (well above normal).

Split-adjusted performance: +22.4% over one month, +41.6% over six months, -2.3% over one year.

In the quarter ended Jun 30, 2026, revenue was $41.57M, up 9.1% from a year earlier, with a net margin of -8.3%.

Short interest was 7.2M shares at the Oct 15 settlement, up 2.0% from the prior report (20.3% of float, 9.4 days to cover).

Market cap$206.1M76.2M shares
Revenue · quarter$41.6M+9.1% YoY
Diluted EPS$-0.05—
P/E · TTM—P/S 1.3×
Net margin-8.3%Gross 51.1%
Dividend yieldNone
52-week range1.18 – 3.30−18.0% from high
Volume5.5M7.48× 20-day avg
Volatility · 60d71.7%Annualised
Short % of float20.3%9.4 days to cover
Net cash-$42.3MCash $19.2M
Next earnings—Not scheduled
Split-adjusted performance
1W +19.7%1M +22.4%3M +20.2%6M +41.6%YTD +96.0%1Y −2.3%3Y +150.5%5Y −47.4%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum77
Revenue growth51
Net margin49
Value (low P/E)—
Size42

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short7.2M+2.0% vs prior
Days to cover9.4Settled Oct 15
% of float20.3%
Short vol. 10d47.8%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
STIMNeuronetics$2.71+19.69%+41.6%+9.1%−8.3%—$206.1M
NEGGNewegg Commerce$9.89+7.62%−68.9%———$207.4MCompare
PDEXPro-Dex Inc New$63.44+5.31%+8.4%+11.0%14.8%16.9$203.0MCompare
UTMDUtah Medical Products$72.42+3.43%+12.4%−14.3%31.5%21.9$229.9MCompare
TLSITriSalus Life Sciences$3.89+11.78%−14.5%+1.7%−80.5%—$239.5MCompare
OSUROraSure Technologies$3.72+5.38%+24.0%−1.9%20.4%—$256.6MCompare
PROFProfound Medical$7.16+2.43%−0.8%+12.3%−384.2%—$261.6MCompare
INFUInfuSystem Holdings$13.15+2.73%+29.7%+2.6%8.7%30.7$261.9MCompare
ANIKAnika Therapeutics$20.40+4.88%+34.9%+15.6%10.1%—$273.0MCompare

News about Neuronetics

All news →
Neuronetics (STIM) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research · 16h ago▲ Positive

Quick answers

What does Neuronetics do?
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood.
What is STIM's market cap?
$206.11M, based on the Nov 4 close of $2.71.
Does Neuronetics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of STIM is sold short?
7.2M shares, 20.3% of float, as of Oct 15, 2026.
What sector is STIM in?
Healthcare, in the Surgical Instruments industry.

About Neuronetics

Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.

HQ: Malvern, PA658 employeesListed Jun 28, 2018neurostar.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology